# RECEIVED FOR CENTRAL FAX CENTER

FEB 0 1 2006, TO/SB/21 (02-04)

Under the Panerwork Raduction Act of 1995 on new	U.S. Pater	Approved for use through 07/31/2008, OMB 0851-0031 of end Tredemark Office; U.S. DEPARTMENT OF COMMERCE on of information unless it displays a valid OMB control number.				
	Application Number	10/584,981				
TRANSMITTAL	Filing Date	January 13, 2006				
FORM	First Named Inventor	BAMDAD, Cynthia C.				
(to be used for all correspondence after initial filing)	Art Unit	N/A				
	Examiner Name	N/A				
Total Number of Pages in This Submission	Attorney Docket Number	13150-70090US				
EN	CLOSURES (Check all the	t apply)				
Fee Trænsmittat Form	Drawing(s)	After Allowance communication to Technology Center (TC)  Appeal Communication to Board				
Fee Attached  Amendment/Reply	Licensing-related Papers Petition	of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)				
After Final	Petition to Convert to a Provisional Application	Proprietary Information				
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Add	Status Letter				
Extension of Time Request	Terminal Disclaimer	Other Enclosure(s) (please identify below):				
Express Abandonment Request	Request for Refund	PTO/SB/08A and PTO/SB/08B				
Information Disclosure Statement	CD, Number of CD(s)					
Gertified Copy of Priority	correspondence is being facsimile	transmitted to (571) 273-8300.				
Response to Missing Parts/ Incomplete Application		· .				
Response to Missing Parts under 37 CFR 1.52 or 1.53						
SIGNATURE	OF APPLICANT, ATTORN	IEY, OR AGENT				
Firm Joseph Hyosuk Kim, Ph.D. Reg. No. 41,425 JHK Law						
Signature	er, Reg. M. 5	6.814				
Date February 1. 2008						
CERTIF	ICATE OF TRANSMISSIO	N/MAILING				
I hereby certify that this correspondence is being to sufficient postage as first class mail in an envelope the date shown below.	I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.					
Typed or printed name Harry Sung Lee	· · · · · · · · · · · · · · · · · · ·					
Signature	slee	Date February 1, 2006				

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form another suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commence, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED CENTRAL FAX CENTER

Docket No. 13150-70090US

FEB 01 2006 PATENT

I hereby certify that on February 1, 2006, which is the date I am signing this certificate, I am transmitting this correspondence and all identified attachments by facsimile to (571) Stop 273-8300. Mail Amendment, Commissioner for Patents, P.O. Box 1450, TREATMENT OF CANCER Alexandria, VA 22313-1450.

Serial No.: 10/564,981 Filed: January 13, 2006

Confirmation No.: N/A

Title: METHODS FOR DIAGNOSIS AND

Applicant: BAMDAD, Cynthia C.

Examiner: N/A Art Unit: N/A

Attorney Docket No.: 13150-70090US

Harry Lec

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### **Information Disclosure Statement**

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed below and on the attached forms PTO/SB/08A and PTO/SB/08B (substitutes for form 1449/PTO) are being brought to the attention of the Examiner for consideration in connection with the examination of the aboveidentified patent application. The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), as an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. Copies of the cited documents can be found in files for application number 09/996,069 filed November 27, 2001 since the same references have been submitted to the Patent Office on November 4, 2005 in connection with application number 09/996,069. Therefore, no copies of the references are included in this submission.

Docket No. 13150-70090US

Application No. 10/564,981

## **English Language Documents:**

	US 3,854,480, ZAFFARONI, December 17, 1974
	US 4,452,775, KENT, June 5, 1984
	US 4,675,189, KENT et al., June 23, 1987
	US 5,075,109, TICE et al., December 24, 1991
	US 5,133,974, PARADISSIS et al., July 28, 1992
	US 5,407,686, PATEL et al., April 18, 1995
	US 5,736,152, DUNN, April 7, 1998
	US 6,127,393, FERNANDEZ-POL, October 3, 2000
	US 6,548,643 B1, MCKENZIE et al., April 15, 2003
	US 2003/0130293 A1, BAMDAD, July 10, 2003
	US 2003/0119834 A1, BAMDAD, June 26, 2003
	US 2002/0156112 A1, BAMDAD et al., October 24, 2002
Ì	U.S. Application No. 09/631,818, BAMDAD, filing date of August 3, 2000 (abandoned)
	WO 95/24929 A2, MATHIOWITZ et al., September 21, 1995 (with English abstract)
	WO 00/34783 A1, BERGSMA et al., June 15, 2000
	WO 00/43791 A2, BAMDAD et al., July 27, 2000
	WO 02/056022 A2, BAMDAD et al., July 18, 2002
	WO 02/078598 A2, WRESCHNER et al., October 10, 2002
	WO 02/22685 A2, KUFE et al., March 21, 2002
	WO 03/020279 A2, BAMDAD, March 13, 2003
	WO 03/020280 A2, BAMDAD, March 13, 2003
	WO 03/089451 A2, HOOGENBOOM et al., October 30, 2003
	WO 2004/005470 A2, PAYNE et al., January 15, 2004
ĺ	WO 2005/019269 A2, BAMDAD, March 3, 2005
	MEERZAMAN et al., "Involvement of the MAP kinase ERK2 in MUC1 mucin signaling", Am.
-	J. Physiol. Lung Cell Mol. Physiol. (2001), 281: L86-L91 SPICER et al., "Molecular Cloning and Analysis of the Mouse Homologue of the Tumor-
	associated Mucin, MUC1, Reveals Conservation of Potential O-Glycosylation Sites,
	Transmembrane, and Cytoplasmic Domains and a Loss of Minisatellite-like Polymorphism",
-	The Journal of Biological Chemistry (1991), 266(23): 15099-15109  VARNER et al. "Integrips and cancer" Correct Opinion in Call Biology (1996), 8, 724, 730
ŀ	VARNER et al., "Integrins and cancer", Current Opinion in Cell Biology (1996), 8: 724-730  HORTON "The guß3 Integrin "Vitropactin Recentor", Int. I. Biochem. Cell Biology (1997), 2005.
	HORTON, "The avβ3 Integrin "Vitronectin Receptor", Int. J. Biochem. Cell Biol. (1997), 29(5): 721-725
	ROSS et al., "The HER-2/neu Oncogene in breast Cancer: Prognostic Factor, Predictive Factor,
-	and Target for Therapy", Stem Cells (1998), 16: 413-428
ı	IN MITNEST AT TRAILED I COMO DESSAGE EN ENGAGE AND MARKET AND ALL CONTRACTOR AND ALL CONT

TREON et al., "MUC-1 Core Protein is Expressed on Multiple Myeloma Cells and is Induced

LIGTENBERG et al., "Cell-associated Episialin is a Complex Containing Two Proteins Derived

by Dexamethasone", Blood (1999), 93(4): 1287-1298

Docket No. 13150-70090US

Application No. 10/564,981

from a Common Precursor", The Journal of Biological Chemistry (1992), 267(9): 6171-6177

CHEN et al., "Labeling of Proteins with [35S]Methionine and/or [35S]Cysteine in the Absence of Cells", Analytical Biochemistry (1999), 269: 179-188

SAWHNEY et al., "Bioerodible Hydrogels Based on Photopolymerized Poly(ethylene glycol)-co-poly(α-hydroxy acid) Diacrylate Macromers", Macromolecules (1993), 26: 581-587

HIEKEN et al., "beta3 Integrin Expression in Melanoma Predicts Subsequent Metastasis", Journal of Surgical Research (1996): 63(1): 169-173(5) (abstract only)

VAILHE et al., "In vitro angiogenesis is modulated by the mechanical properties of fibrin gels and is related to alpha(v)beta3 integrin localization", In Vitro Cell Dev. Biol. Anim. (1997), 33(10): 763-773 (abstract only)

PEGRAM et al., "Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment", Journal of Clinical Oncology (1998), 16: 2659-2671 (abstract only)

FRALEY et al., "New generation liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids", *Trends in Biochemical Sciences*(1981), 6: 77-80 (abstract only)

KUFE et al., "Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors", Hybridoma (1984), 3(3): 223-232 (abstract only)

SCHNEIDER et al., "nm23 expression in advanced and borderline ovarian carcinoma", Anticancer Res. (1996), 16(3A): 1197-1202 (abstract only)

MAO et al., "Loss of nm23 expression predicts distal metastases and poorer survival for breast cancer", Int. J. Oncol. (2001), 18(3): 587-591 (abstract only)

GREGORIADIS, "Liposomes for drugs and vaccines", Trends in Biotechnology (1985), 3(9): 235-241 (abstract only)

#### Foreign Language Document:

WO 92/07000A1, CHAMBON et al., April 30, 1992 (with English abstract)

It is respectfully requested that the Examiner indicate consideration of the cited references by returning copies of the attached forms PTO/SB/08A and PTO/SB/08B (substitutes for form 1449/PTO) with initials or other appropriate marks, and that the references be made of record as cited references in the application.

This Information Disclosure Statement is being filed within three (3) months from the filing date and before the mailing date of a First Office Action on the merits in the above-identified case. Therefore, no fee is required.

The Commissioner is authorized to charge JHK Law's Deposit Account No. 502486 for any fees required under 37 CFR §§ 1.16 and 1.17 and to credit any overpayment to said Deposit Account No. 502486.

Docket No. 13150-70090US

Application No. 10/564,981

le, Res. M. 56, 814

February 1, 2006

Date

Respectfully submitted,

Joseph Hyosuk Kim, Ph.D.

Reg. No. 41,425

Attorney for Applicants

JHK Law

P.O. Box 1078

La Canada, CA 91012-1078

Telephone: (818) 249-8177

Facsimile: (818) 249-8277

PTO/9B/08A (08-03)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

JHK LAW

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Substitute for form 1449/RTO

Complete if Known Substitute for form 1449/PTO Application Number 10/564,981 Filing Date January 13, 2006 INFORMATION DISCLOSURE First Named Inventor BAMDAD, Cynthia C. STATEMENT BY APPLICANT Art Unit N/A (Use as many sheets as necessary) Examiner Name N/A 13150-70090US Attorney Docket Number

Examiner		I Dooremont Niembor	Dublication Care	Manual of Pate state	Barrier Barrier 10am
Initiate*	Cite No,1	Document Number  Number-Kind Code <sup>2 (FAmount)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/B.M./	A1	<sup>US-</sup> 3,854,480	12-17-1974	ZAFFARONI	whole document
/B.M./	A2	<sup>US-</sup> 4,452.775	06-05-1984	KENT	whole document
/B.M./	А3	<sup>US-</sup> 4,675,189	06-23-1987	KENT et al.	whole document
/B.M./ <del>'B.M./</del>	<b>A4</b>	<sup>US-</sup> 5,075,109	12-24-1991	TICE et al.	whole document
	A5	<sup>us-</sup> 5,133,974	07-28-1992	PARADISSIS et al.	whole document
/B.M./	A6	us- 5,407,686	04-18-1995	PATEL et al.	whole document
/B <b>.M</b> ./	A7	us- 5,736,152	04-07-1998	DUNN	whole document
D.W./	A8	<sup>US-</sup> 6,127,393	10-03-2000	FERNANDEZ-POL	whole document
<u>/</u> B.M./	A9	<sup>US-</sup> 6,548,643 B1	04-15-2003	MCKENZIE et al.	whole document
3.M./	A10	<sup>us-</sup> 2003/0130293 A1	07-10-2003	BAMDAD	whole document
B.M./	A11	<sup>US-</sup> 2003/0119834 A1	06-26-2003	BAMDAD	whole document
<u>/B.M./</u>	A12	<sup>US-</sup> 2002/0156112 A1	10-24-2002	BAMDAD et al.	whole document
/B.M./	A13	<sup>US-</sup> 09/631.818 (08-03-2000)		BAMDAD	whole document .
	<u> </u>	U\$-			
		US-			
		US-			
	L ]	US-			
		US-			
		U\$-			

		FORE	IGN PATENT DOCU	MENTS		
Exeminer Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentes or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T
0,0000000000000000000000000000000000000	<b>*****</b>	<del> \\\O-92/07000</del>	04-30-1992	CHAMBON et al.	whole document	
	B2	WO 95/24929	09 21 1995	MATHIOWITZOLOL	whole decument	
	В3	WO 00/34783	06-15-2000	BERGSMA et al	whole document	
	B4	WO 00/43791	07-27-2000	BAMDAD et al	whole document	
	B5	WO 02/056022 A2	07-18-2002	BAMDAD et al.	whole document	
doccoccoccoccocc	186	VVQ 02/076596 AZ	10-10-2002	WRESCHNER et al.	whole document	0000000

	The state of the s		
Examiner	/Brian Mcdowell/	Date	44/47/0000
Signature		Considered	11/17/2008
L		Considering	

"EXAMINE: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant, "Applicant's unique citation designation number (optional). "See kinds Codes of USPTO Parent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. "Enter Office that issued the document, by the two-letter code (MIPO Standard ST.3). "For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. "Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 If possible." Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, P.O. 8ox 1450, Alexandria, VA 22313-1450, D. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.

Approved for use through 07/31/2008. OMB 0651-631

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMARCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

stitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

8182498277

Lo	mpiete ii Known
Application Number	10/564,981
Filing Date	January 13, 2006
First Named Inventor	BAMDAD, Cynthia .
Art Unit	N/A
Examiner Name	N/A
Attorney Docket Number	13150-7009048

		1	U. S. PATENT		
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (*/mount)</sup>	Publication Date MM-DD-YYYY	Name of Petenties or Applicant of Cited Document	Pages, Columns, Lines, Where Rolevant Passages or Relevant Figures Appear
		US-			
		US-			
		US.			
		US-	N.		
		US-	1		
		US-			
		US-	<u> </u>		
		US-			
		US-	1		
		u\$-		The state of the s	
		U\$			
***************************************		UŞ-			
		U\$-		1	

		FORE	GN PATENT DOCL	IMENTS &		
Examiner Initiats*	Cite No.1	Foreign Patent Document	Publication Deta	Name of Patentee or Applicant of Oted Document	Pages, Columna, Lines, Where Relevent Passages	T
· <del></del>		Country Code <sup>2</sup> "Number * King Code <sup>2</sup> (If Isnown)	MM-DD-YYYY		Or Relevant Figures Appear	T
	B7	WO 02/22685 A2/	03-21-2002	KUFE et al.	whole document	
	B8	WO 03/020279/A2	03-13-2003	BAMDAD	whole document	
	B9	WO 03/020280 A2	03-13-2003	BAMDAD	whole document	
	B10		10-30-2003	HOOGENBOOM et al.	whole document	
	B11	WO 2004/005470 A2		,	vittole document	Г
	B12	WO 2005/019269 A2	03-03-2005	BAMDAD	whole document	

Evamine /Brian Mcdowell/ Date Signature

"EXAMINER: Initial of reference considered, whether or not obtain is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 2 See Kinda Codes of USPTO Patent occuments at <a href="https://www.uspto.cov">www.uspto.cov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanesse patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to the (and by the USPT) to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gethering, preparing, and submitting the completed application form to the USPTO. Time will valy depending upon the individual case. Any configents on since amount of time you require to complete his form and/or suppertions for reducing this burden, should be sent to the Chief Information Officer, U.S. Pearl and Tradement Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need essistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

8182498277

Under the Paperwork Reduction Act of 1995, no persons as	U.S. Patent re-required to respond to a collection	PTO/SB/038 (08-06) Approved for use through 07/31/2006. OMB 0851-0931 and Trademark Office; U.S. DEPARTMENT OF COMMERCE of information unless it contains a valid OMB control symber.
Substitute for form 1449/PTO		Complete If Known
	Application Number	10/564,981
INFORMATION DISCLOSURE	Filing Date	January 13, 2006
STATEMENT BY APPLICANT	First Named Inventor	BAMDAD, Cynthia C.
(Use as many sheets as necessary)	Art Unit	N/A
	Examiner Name	N/A
Sheet 1 of 2	Attorney Docket Number	13150-70090US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C1	MEERZAMAN et al., "Revolvement of the MAP kinase ERK2 in MUC1 medin signaling", Am. J. Physiol, Lung Cell Mol. Physiol. (2001), 281: L86-L91	
	C2	SPICER et at., "Molecular Cloning and Analysis of the Mouse Homologue of the Tumor-associated Mucin, MUC1, Roveals Conservation of Potential & Glycosylation Sites, Transmergorane, and Cytoplasmic Domains and a Loss of Minisptellite-like Polymorphism", The Yournal of Biological Chemistry (1991), 266(23): 15099-15109	
	СЗ	VARNER et al., "Integrins and cander", Current Opinion in Cell Biology (1996), 8: 724-730	
	C4	HORTON, "The avb3 Integrin "Vitronectin Acceptor", Int. J. Biochem. Cell Biol. (1997), 29(5): 721-725	
	C5	ROSS et al., 'The HER-2/neu Oncogene a bresst Calicer: Prognostic Factor, Predictive Factor, and Target for Therapy', Stem Cells (1998), 16: 413-428	
	<b>C</b> 6	TREON et al., "MUC-1 Core Protein is Expressed on Multiple Ayelome Cells and is Induced by Dexamethasone", Blood (1999) 93(4): 1287-1298	
	C7	LIGTENBERG et al., "Cell-associated Episialin is a Complex Containing Two Proteins Derived from a Common Preparaor", The Journal of Biological Chemistr, (1992), 267(9): 6171-6177	
	æ	CHEN et al., "Labeling of Proteins with [355]Methionine and/or [355]Cysteine in the Absence of Cells", Analytical Biochemistry (1999), 269: 179-188	
	C9	SAWHNEY et al., "Bioerodible Hydrogels Based on Photopolymerized Poly(ethylene slycol)-co-poly(e-hydroxy acid) Disprylate Macromers", Macromolecules (1993), 26: 581-587	_
	C10	HIEXEN et al., "beta3 Integrin Expression in Melanoma Predicts Subsequent Metastasis", Journal of Surgical Research (1998): 63(1): 169-173(5)	

Examiner /Brian Mcdowell/ Date 11/17/2008 Signature Considered

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant to piece a check mark here if English language Translation to estauched.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to progenes) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathsing, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the hid/hidual case. Any comments on the apout of time you require to complete this form and/or auggestions for reducing this hunden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-785-9199) and select option 2.

11/17/2008

Under th	e Paperw	ork Reduction A	ct.of, 1995, no persons er	U.S. Petern U.S. Petern re required to respond to a collection	end Tredemark Office of Information unless		51-0931 MBRCE	
Substitute for	form 1441	e/PTO		A No show Mouse have	Complete if Kn	own		
				Application Number	10/564,981			
INFORMATION DISCLOSURE				Filing Date	January 13, 20	006		
STATE	STATEMENT BY APPLICANT			First Named Inventor	BAMDAD, Cyl	nthia C.		
0				Art Unit	N/A			
•	200 00 111	3.00.00	, accessery,	Examiner Name	N/A			
Sheet 2		of	2	Attorney Docket Number	13150-700901	JS/		
					<u> </u>			
		W	NON PAT	ENT LITERATURE DOC	CUMENTS /	,		
Examiner Initials*	Cite No.1	Include no the item (	of the author (in	n CAPITAL LETTERS), title urnal, serial, symposium, ca ), publisher, city and/or cour	of the article (who	page(s), volume-issue	T <sup>2</sup>	
	C11	VAILHE et a alpha(v)beta	. "In vitro anglogenes	is is modulated by the mechani , In Vitro Cell Dev. Biol. Anim. (	ical properties of fib	rin gets and is related to		
	C12	PEGRAM et al., "Phase il studi of receptor-enhanced chemosegaltivity using recombinant humanized anti- p185HER2/neu monocional antibady plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy "estment", Journal of Clipical Oncology (1998), 18: 2659-2671						
C13 FRALEY et al., "New generation delivery of nucleic acids", Trends				n liposomes: the engineering of an efficient vehicle for intracellular ds in Blachemical Spences(1981), 6: 77-80				
	C14	KUFE et al. benign brea	"Differential reactivi st lumors", Hybridom	viry of a novel conoclonal antibody (DF3) with human malignant versus orna (1984). 3(3): 223-232				
	C15	SCHNEIDER 16(3A): 1197	l et al., "nm23 express -1202	sion in divanced and borderline	ovarian carcinoma	, Anticancer Res. (1996),		
	C16	MAO et al., * Oncol. (2001	Loss of nm23 express), 18(3); 587-591	ion predicts distal metastasses	and poorer survival f	or breast cancer", Int. J.		
	C17	GREGORIA	DIS, *Liposomes for	drugs and vaccines", Trends	in Biotechnology (	1985). 3(9): 235-241		
							-	
Examiner					Dete			
	1 8 /	Rrian Moc	lowell/		Date	11/17%/2008		

Considered

If you need assistance in completing the form, cell 1-800-PTO-9189 (1-800-786-9199) and select option 2.

/Brian Mcdowell/

Signature

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 Applicants unique citation designation number (optional). 2 Applicant is to place a check mark here it English language Transtation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by in USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments be the argument of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Pademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: